Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Yang et al

Affiliations

¹ Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
² Department of Internal Medicine, Division of Gastroenterology, Hepatology and Motility, University of Kansas, Kansas City, Kansas, USA.
³ Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA asakurab@medicine.bsd.uchicago.edu.

Comment

Shintaro Akiyama et al. Ann Rheum Dis. 2023 Apr.

. 2023 Apr;82(4):e80.

doi: 10.1136/annrheumdis-2021-219855. Epub 2021 Jan 15.

¹ Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA.
² Department of Internal Medicine, Division of Gastroenterology, Hepatology and Motility, University of Kansas, Kansas City, Kansas, USA.
³ Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, USA asakurab@medicine.bsd.uchicago.edu.

No abstract available

Keywords: COVID-19; autoimmune diseases; epidemiology.

Conflict of interest statement

Competing interests: None declared.

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
Akiyama S, Hamdeh S, Micic D, Sakuraba A. Akiyama S, et al. Ann Rheum Dis. 2021 Mar;80(3):384-391. doi: 10.1136/annrheumdis-2020-218946. Epub 2020 Oct 13. Ann Rheum Dis. 2021. PMID: 33051220
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.
Yang H, Xu J, Shi L, Duan G, Wang Y. Yang H, et al. Ann Rheum Dis. 2023 Apr;82(4):e79. doi: 10.1136/annrheumdis-2020-219821. Epub 2021 Jan 15. Ann Rheum Dis. 2023. PMID: 33452002 No abstract available.